Pharma BD Deal Intelligence
A $400M upfront, $1.2B-total FcRn-antibody acquisition that ended in outright legal defeat: Alexion killed the lead asset (ALXN1830) in 2021, and Delaware's Chancery Court ruled it breached its earnout obligations, ordering roughly $220M paid to Syntimmune's former shareholders on top of the failed program.
Lead asset scrapped in 2021, litigation found the buyer breached the merger agreement in bad faith, and a Delaware court ordered roughly $220M paid to former Syntimmune shareholders on top of the failed program — a rare deal that aged into an outright legal loss, not just an underperformance.
Full analysis, sources & comparables →Alexion's $400M upfront for Syntimmune buys access to a dual-mechanism FcRn antibody that could expand the company beyond complement into a broad autoimmune…
Delaware Chancery ruled AstraZeneca's Alexion failed to use commercially reasonable efforts to develop ALXN1830, awarding $130M to former Syntimmune…
On June 11, 2025 the Delaware Court of Chancery awarded former Syntimmune stockholders $180,944,915.32 in expectation damages for Alexion's breach of its…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Alexion announced acquisition of New York-based Syntimmune in September 2018 for $400M upfront plus up to $800M in milestones tied to eight ALXN1830 development goals (total $1.2B); the deal closed November 2018. The asset was SYNT001 (renamed ALXN1830), a first-in-class anti-FcRn monoclonal antibody for warm autoimmune hemolytic anemia and pemphigus. After AstraZeneca acquired Alexion in 2021, a portfolio review scrapped ALXN1830 in December 2021, triggering breach-of-contract litigation by Syntimmune's former stockholders (via Shareholder Representative Services). The Delaware Court of Chancery found for the stockholders in two post-trial rulings: a September 5, 2024 decision holding Alexion breached its commercially-reasonable-efforts (CRE) obligation and awarding $130M on the first unpaid milestone, and a June 11, 2025 damages decision awarding an additional $180.94M in expectation damages (the probability-weighted value of the forgone earnouts at the time of breach). Combined liability is roughly $310M before interest; with pre- and post-judgment interest the June 2025 award alone is expected to total ~$220M. The court found Alexion's termination was driven by ~$500M in promised AstraZeneca merger synergies rather than a good-faith development assessment. No FcRn asset ultimately reached market for Alexion; argenx's efgartigimod (2021) and others later defined the FcRn category. The case stands as a leading Delaware precedent on CRE earnout obligations in pharma M&A.
Lead asset scrapped in 2021, litigation found the buyer breached the merger agreement in bad faith, and a Delaware court ordered roughly $220M paid to former Syntimmune shareholders on top of the failed program — a rare deal that aged into an outright legal loss, not just an underperformance.
Assessment window: 5yr post-close.
Warm autoimmune hemolytic anemia (wAIHA) is a rare IgG-mediated autoimmune disorder where pathogenic antibodies bind red blood cells at body temperature, triggering premature destruction and life-threatening anemia. Pemphigus vulgaris and pemphigus foliaceus are rare blistering autoimmune skin diseases also driven by pathogenic IgG. Both indications had no FDA-approved targeted therapy in 2018; standard care relied on corticosteroids, rituximab, and splenectomy.
At deal time (September 2018), no FcRn inhibitor had reached the market and Syntimmune's SYNT001 (later ALXN1830) was positioned as a first-in-class anti-FcRn monoclonal antibody for IgG-mediated rare diseases. The acquisition gave Alexion a beachhead in autoimmune complement-adjacent diseases beyond its complement franchise. The competitive landscape evolved sharply post-deal: argenx's efgartigimod (Vyvgart) became the first FDA-approved FcRn antagonist in December 2021 for generalized myasthenia gravis; UCB's rozanolixizumab (Rystiggo) followed in 2023. Johnson & Johnson's nipocalimab (acquired via Momenta) emerged as the leading FcRn candidate specifically in wAIHA, with Phase 3 ENERGY trial advancing. For pemphigus, standard care remains rituximab plus corticosteroids; Vyvgart was approved in pemphigus in 2025. ALXN1830 was scrapped in December 2021 after AstraZeneca's acquisition of Alexion; Syntimmune shareholders subsequently won a $130M breach-of-contract verdict in Delaware Chancery (2024) for failure to pursue commercially reasonable milestone efforts. See https://www.fiercepharma.com/pharma/after-2018-merger-azs-alexion-syntimmune-shareholders-win-130m-breach-contract-suit
In a June 11, 2025 post-trial damages ruling, the Delaware Court of Chancery awarded former Syntimmune stockholders $180.94M in expectation damages for Alexion's breach of its commercially-reasonable-efforts obligation to develop ALXN1830 -- on top of the separate $130M milestone judgment from September 2024. Combined liability is ~$310M before interest (~$220M with interest on the new award). The court tied the program's termination to AstraZeneca merger synergies rather than a good-faith development decision.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Alexion Pharmaceuticals Inc. / Syntimmune, Inc. (this deal) | 2018 | $1.2B | 14 |
| Alexion Pharmaceuticals Inc. / Synageva BioPharma | 2015 | $8.4B | 36 |
| Alexion Pharmaceuticals Inc. / Wilson Therapeutics AB | 2018 | $855M | 20 |
| Alexion Pharmaceuticals Inc. / Portola Pharmaceuticals, Inc. | 2020 | $1.4B | — |
| Alexion Pharmaceuticals Inc. / Achillion Pharmaceuticals, Inc. | 2019 | $1.2B | — |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Servier / Shire plc (Oncology Business) | 2018 | $2.4B | 88 |
← Browse all deals · How we score deals
More: 2018 deals · Alexion Pharmaceuticals Inc. deals · Hematology deals